Martindale: The Complete Drug Reference 40th Edition

Product Description

The new edition of Martindale: The Complete Drug Reference, provides you with practical, evidence-based, global guidance, allowing you to quickly understand the characteristics of drugs and their clinical uses.

Over 120 new monographs include:

• New antibacterials, such as delafloxacin, eravacycline, omadacycline, ozenoxacin, and plazomicin

• Further antivirals, including drugs active against HIV (bictegravir, dapivirine, doravirine, ibalizumab), smallpox (tecovirimat), cytomegalovirus (letermovir), influenza (baloxavir marboxil), and hepatitis C (glecaprevir, pibrentasvir, voxilaprevir)

• New treatment options for migraine (erenumab, fremanezumab, galcanezumab), narcolepsy (solriamfetol), hyperkalaemia (sodium zirconium cyclosilicate), postpartum depression (brexanolone), eosinophilic asthma (benralizumab), hypoactive sexual desire disorder (bremelanotide), glaucoma (netarsudil), African trypanosomiasis (fexinidazole), and irritable bowel syndrome (tenapanor)

• New antidiabetic drugs, including ertugliflozin, evogliptin, semaglutide, and sotagliflozin

• Further antineoplastics for treating cancers including PARP inhibitors (niraparib, rucaparib, talazoparib), PI3K inhibitors (alpelisib, copanlisib, duvelisib), and CAR-T therapies (axicabtagene ciloleucel, tisagenlecleucel)

• Novel targeted treatments for retinal dystrophy (voretigene neparvovec), neurotrophic keratitis (cenegermin), paroxysmal nocturnal haemoglobinuria (ravulizumab), hereditary transthyretin amyloidosis (inotersen, patisiran), spinal muscular atrophy (nusinersen), and hereditary angioedema (lanadelumab)